Qi Deng

This early-phase trial tests a new type of immune cell therapy called GPRC5D CAR-T in 18 people with relapsed or refractory plasma cell disorders, such as multiple myeloma. The therapy involves giving patients a single infusion of their own modified immune cells designed to attac…

This early-phase study tests a new type of CAR-T cell therapy (FO33 CAR-T) for people with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target a protein called CD33 found on mos…

This early-phase study tests whether combining two drugs (Zuberitamab and Orelabrutinib) can help people with immune thrombocytopenia (ITP) or autoimmune hemolytic anemia (AIHA) that hasn't responded to other treatments. The drugs work together to calm the immune system and stop …

This early-phase study tests a new type of CAR-T cell therapy that works inside the body, avoiding the complex and costly lab process usually needed. It targets two markers (CD19 and BAFF-R) on cancer cells in people with relapsed or hard-to-treat B-cell leukemia or lymphoma. The…